Stock listing
ELOX Stock Price, News, Filings & Events — Eloxx Pharmaceuticals, Inc.
Selected listing: ELOX · OTC · USD · US
This page tracks Eloxx Pharmaceuticals, Inc.'s ELOX:OTC listing on OTC in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ELOX:OTC. ELOX:OTC is the stock-level entry point for investors researching Eloxx Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Eloxx Pharmaceuticals, Inc. is a public company traded under the ticker ELOX in the American market. The company has a market capitalization of approximately $1.19 million. Eloxx focuses on developing therapies for genetic diseases caused by nonsense mutations.
- Ticker
- ELOX:OTC
- Asset type
- Stock
- Market cap
- $1.2M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Eloxx Pharmaceuticals, Inc. ELOX:OTC stock context
This page tracks Eloxx Pharmaceuticals, Inc.'s ELOX:OTC listing on OTC in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ELOX:OTC. ELOX:OTC is the stock-level entry point for investors researching Eloxx Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Eloxx Pharmaceuticals, Inc. is a public company traded under the ticker ELOX in the American market. The company has a market capitalization of approximately $1.19 million. Eloxx focuses on developing therapies for genetic diseases caused by nonsense mutations.
Latest news from Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
November 13, 2023
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 ...
October 10, 2023
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 ...
October 9, 2023
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 19, 2023
Eloxx Pharmaceuticals, Inc. earnings calls
Research Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for ELOX:OTC.
Eloxx Pharmaceuticals, Inc. company profile
View the public company page for Eloxx Pharmaceuticals, Inc. on 6ix.
Eloxx Pharmaceuticals, Inc. news
Read company news and market updates connected to Eloxx Pharmaceuticals, Inc..
Eloxx Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Eloxx Pharmaceuticals, Inc..